Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

Femara® Virtual Exhibit Booth

FEMARA® Virtual Booth interactively matches your experience to that of attendees at international scientific Congresses such as the 2010 European Breast Cancer Congress.

Move your mouse below for more information: Enter on the numbered exhibit panels or the titles listed below

Femara | Virtual Exhibit Booth Femara | Overall risk of recurrence of breast cancer initially peaks 2 to 3 years after diagnosis Femara | Femara significantly reduced the risks of distant metastases and overall recurrence during the initial peak in risk Femara | FEMARA provides a generally well-tolerated safety profile over time Femara | BIG 1-98: a unique study of adjuvant treatment Femara | BIG 1-98 efficacy results confirm the superiority of FEMARA versus tamoxifen Femara | FEMARA is the only aromatase inhibitor versus tamoxifen that significantly reduced the early risk of distant metastases